The therapy is designed to work even if different patients express different cancer "flags." More critically, it targets multiple flags within a single patient's heterogeneous tumor. This reduces the risk of cancer cells that lack a single target surviving and causing treatment resistance, aiming for deeper and more durable responses.

T-cell receptor (TCR) therapies offer a significant advantage over monoclonal antibodies by targeting intracellular proteins. They recognize peptides presented on the cell surface, effectively unlocking 90% of the proteome and requiring far fewer target molecules (5-10 copies vs. 1000+) to kill a cancer cell.

A therapeutic approach called "T-cell engagers" or "BiTEs" uses engineered antibodies with two different heads. One side binds to a cancer cell, while the other binds to a nearby T-cell. This effectively brings the killer cell and the target together, leveraging the body's existing immune cells without genetic modification.

While targeting intracellular peptide-MHC complexes opens the entire proteome as potential cancer targets, the approach is limited by HLA restriction. This means a drug might only be applicable to 30-40% of patients, a major commercial and clinical drawback that complicates development despite the potential for exquisite specificity.

Cytospire targets well-validated antigens like EGFR, which were previously 'undruggable' by CD3 engagers due to severe toxicity on healthy cells. Their gamma delta T-cell platform solves this by enabling 'context-dependent killing,' discriminating between tumor and healthy tissue. This safety profile could unlock a portfolio of solid tumor targets previously considered too dangerous for this drug class.

Many promising solid tumor antigens (e.g., PSMA, HER2) are also on normal tissues, making them too toxic for T-cell engagers. By using masks that are cleaved only in the tumor microenvironment, these "dirty" targets become viable, dramatically expanding the therapeutic landscape for solid cancers.

Infinitopes' platform uses immunopeptidomics to directly measure peptides on a tumor's surface. This contrasts with competitors like Moderna and BioNTech, who rely on computational predictions from DNA sequencing. This "measure, don't predict" approach aims for more reliable identification of potent immune targets.

The first approved peptide MHC T-cell engager (KimTrack) has stability and manufacturing issues. DEC-Bio's DBTV technology stabilizes T-cell receptors (TCRs) to behave like monoclonal antibodies, enabling a longer half-life (days vs. hours), simpler manufacturing, and more convenient patient dosing. This technical fix creates a significant commercial advantage.

For solid tumors, the critical design hurdle for T-cell engagers is achieving selectivity. Most target antigens are also expressed at low levels on healthy cells, so molecules must be engineered to attack tumors with high antigen expression while sparing healthy tissue to avoid on-target, off-tumor toxicity.